Goal 2: Reduce Human Disease

Is “renewal” of R01 grants, competitive or not, justifiable?

Does NIH intend to develop a new milestone-based grant system and introduce accountability with regards to reaching solid metrics and useful, quantifiable research goals and milestones? Does NIH intend to introduce a truly non-conflicted and independent grant review system, similar to the review system and accountability of the FDA, to increase research efficiency? Should the public be informed annually how effective the R01-type grant system has been in any given year regarding generation of results with quantifiable benefit to the public? Should the NIH “renew” grants that did not meet milestones and produced useful outcomes? Should the NIH determine the average cost of developing a useful idea by reporting efficiency?

Tags (Keywords associated with the idea)

Voting

-4 net votes
16 up votes
20 down votes
Active
Idea No. 384